Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044544 | 0.85 | KMT2A (0.44) | MEN1GAAKMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL27876362 | 0.85 | SMN1; SMN2 (0.44) | MEN1GAAKMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL13984717 | 0.83 | SMN1; SMN2 (0.43) | MEN1GAAKMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL6178284 | 0.79 | P2RX7 (0.43) | P2RX7L3MBTL1CYP3A4MAPTKDM4E | |
| SCHEMBL29026089 | 0.78 | LMNA (0.43) | MEN1GAAKMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL30288171 | 0.78 | LMNA (0.43) | MEN1GAAKMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL462122 | 0.76 | CASP1 (0.63) | MEN1GAAKMT2ASMN1; SMN2P2RX7 | |
| SCHEMBL13044576 | 0.75 | MC4R (0.46) | MEN1KMT2AMAPK1 | |
| SCHEMBL20346327 | 0.74 | KMT2A (0.47) | MEN1GAAKMT2ASMN1; SMN2BRD4 | |
| SCHEMBL1647591 | 0.74 | P2RX7 (0.51) | MEN1GAAKMT2ASMN1; SMN2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123931-B1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030055065-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2003-03-20 | — | — | US | disclosed |
| EP-0819128-B1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | SCHERING CORP (US) | 2002-07-10 | — | — | EP | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-0723540-B1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1123931-A1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-5891872-A | INHIBIT FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| US-5807852-A | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5807853-A | Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5719148-A | FARNESYL-PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5714609-A | FORMING CHEMICAL INTERMEDIATE BY NITRATING SUBSTITUTED BENZO/5,6/CYCLOHEPTA/1,2-B/PYRIDINE WITH TETRABUTYLAMMONIUM NITRATE AND TRIFLUOROACETIC ANHYDRIDE IN SOLVENT AT REDUCED TEMPERATURE | SCHERING CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0819128-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | SCHERING CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5700806-A | FARNESYL PROTEIN TRANSFERASE ENZYME INHIBITOR, ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696121-A | 4-(3-BROMO 8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE-11-YL)-N-(3 -PYRIDINYL)-1-PIPERAZINECARBOXIDE; ANTITUMOR AGENT; FARNESYL PROTEIN TRANSFERASE INHIBITOR | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1996031111-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | SCHERING CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0723540-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010516-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055065-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | MEN1 485/4885GAA 1569/4885KMT2A 4274/4885 |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | MEN1 485/4885GAA 1569/4885KMT2A 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.